

Douglas W Blayney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6191023/publications.pdf>

Version: 2024-02-01

205
papers

12,195
citations

41344

49
h-index

25787

108
g-index

208
all docs

208
docs citations

208
times ranked

11096
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors. <i>JAMA Network Open</i> , 2022, 5, e2145446.	5.9	9
2	Cancer Biosimilars—A Regulatory Success So Far, but Value Still to Be Determined. <i>JAMA Oncology</i> , 2022, 8, 520.	7.1	2
3	Surgical solution for a paraneoplastic neurodegenerative disorder. <i>Trauma Surgery and Acute Care Open</i> , 2022, 7, e000928.	1.6	0
4	Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review. <i>Cancer Treatment Reviews</i> , 2022, 109, 102427.	7.7	11
5	Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance. <i>European Urology Open Science</i> , 2021, 23, 20-29.	0.4	11
6	Benchmark Method for Cost Computations Across Health Care Systems: Cost of Care per Patient per Day in Breast Cancer Care. <i>JCO Oncology Practice</i> , 2021, 17, e1403-e1412.	2.9	3
7	Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model. <i>JCO Oncology Practice</i> , 2021, 17, e1688-e1697.	2.9	7
8	Limited English Proficiency and Disparities in Health Care Engagement Among Patients With Breast Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e1837-e1845.	2.9	13
9	Development and Use of Natural Language Processing for Identification of Distant Cancer Recurrence and Sites of Distant Recurrence Using Unstructured Electronic Health Record Data. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 469-478.	2.1	14
10	Impact of adding plinabulin to pegfilgrastim for the prevention of TAC chemotherapy (Chemo) induced neutropenia (CIN), on patient quality of life (QoL).. <i>Journal of Clinical Oncology</i> , 2021, 39, e24031-e24031.	1.6	1
11	Chemotherapy induced profound neutropenia (PN) in patients (pt) with breast cancer (BC) after chemotherapy and plinabulin (Plin) plus pegfilgrastim (Peg) combination versus (vs) peg alone: Final phase 3 results from protective-2 (BPI-2358-106).. <i>Journal of Clinical Oncology</i> , 2021, 39, 546-546.	1.6	3
12	Treatment and Monitoring Variability in US Metastatic Breast Cancer Care. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 600-614.	2.1	5
13	Head-to-head comparison of single agent (SA) plinabulin (Plin) versus pegfilgrastim (Peg) for the prevention of chemotherapy-induced neutropenia (CIN) in the phase 3 trial PROTECTIVE-1.. <i>Journal of Clinical Oncology</i> , 2021, 39, 547-547.	1.6	2
14	Identification of patients at high risk for preventable emergency department visits and inpatient admissions after starting chemotherapy: Machine learning applied to comprehensive electronic health record data.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1511-1511.	1.6	0
15	Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention.. <i>Journal of Clinical Oncology</i> , 2021, 39, 533-533.	1.6	6
16	Diverse patient trajectories during cytotoxic chemotherapy: Capturing longitudinal patient-reported outcomes. <i>Cancer Medicine</i> , 2021, 10, 5783-5793.	2.8	5
17	Health management via telemedicine: Learning from the COVID-19 experience. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 2536-2540.	4.4	16
18	Headache outcomes of a sleep behavioral intervention in breast cancer survivors: Secondary analysis of a randomized clinical trial. <i>Cancer</i> , 2021, 127, 4492-4503.	4.1	2

#	ARTICLE	IF	CITATIONS
19	Pioneering Cancer Quality: Lessons From Dr Joe Simone. JCO Oncology Practice, 2021, 17, 505-506.	2.9	0
20	Association of treatment type with patient-reported quality of life in cancer distress screening.. Journal of Clinical Oncology, 2021, 39, 178-178.	1.6	6
21	Preventing 30-day readmissions for patients with cancer: A root-cause analysis.. Journal of Clinical Oncology, 2021, 39, 226-226.	1.6	0
22	Reply to Ritzwoller et al. JCO Clinical Cancer Informatics, 2021, 5, 1026-1027.	2.1	0
23	Spotlight on International Quality: COVID-19 and Its Impact on Quality Improvement in Cancer Care. JCO Global Oncology, 2021, 7, 1513-1521.	1.8	2
24	Machine Learning Applied to Electronic Health Records: Identification of Chemotherapy Patients at High Risk for Preventable Emergency Department Visits and Hospital Admissions. JCO Clinical Cancer Informatics, 2021, 5, 1106-1126.	2.1	13
25	Cortical Brain Age from Pre-treatment to Post-chemotherapy in Patients with Breast Cancer. Neurotoxicity Research, 2020, 37, 788-799.	2.7	22
26	Predicting Patient Reported Outcomes of Cognitive Function Using Connectome-Based Predictive Modeling in Breast Cancer. Brain Topography, 2020, 33, 135-142.	1.8	10
27	Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer. JAMA Oncology, 2020, 6, e204429.	7.1	22
28	Association between patient-initiated emails and overall 2-year survival in cancer patients undergoing chemotherapy: Evidence from the real-world setting. Cancer Medicine, 2020, 9, 8552-8561.	2.8	16
29	Leveraging Digital Data to Inform and Improve Quality Cancer Care. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 816-822.	2.5	18
30	Clinical Documentation to Predict Factors Associated with Urinary Incontinence Following Prostatectomy for Prostate Cancer. Research and Reports in Urology, 2020, Volume 12, 7-14.	1.0	5
31	International Perspective on the Pursuit of Quality in Cancer Care: Global Application of QOPI and QOPI Certification. JCO Global Oncology, 2020, 6, 697-703.	1.8	3
32	Is it possible to automatically assess pretreatment digital rectal examination documentation using natural language processing? A single-centre retrospective study. BMJ Open, 2019, 9, e027182.	1.9	6
33	Comparison of orthogonal NLP methods for clinical phenotyping and assessment of bone scan utilization among prostate cancer patients. Journal of Biomedical Informatics, 2019, 94, 103184.	4.3	12
34	Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer. Cancer, 2019, 125, 943-951.	4.1	15
35	Utilization of Prostate Cancer Quality Metrics for Research and Quality Improvement: A Structured Review. Joint Commission Journal on Quality and Patient Safety, 2019, 45, 217-226.	0.7	7
36	Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN). Blood, 2019, 134, 4861-4861.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Machine Learning Approaches for Extracting Stage from Pathology Reports in Prostate Cancer. <i>Studies in Health Technology and Informatics</i> , 2019, 264, 1522-1523.	0.3	7
38	Extracting Patient-Centered Outcomes from Clinical Notes in Electronic Health Records: Assessment of Urinary Incontinence After Radical Prostatectomy. <i>EGEMS (Washington, DC)</i> , 2019, 7, 43.	2.0	8
39	PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 795-803.	4.9	17
40	A phase II trial with the combination of plinabulin (plin) pegfilgrastim (peg): Evaluation of the reversal of peg's immune-suppressive potential by the addition of plin to peg.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4-4.	1.6	0
41	Comparison of pegfilgrastim (Peg), plinabulin (Plin), and the combination for chemotherapy (Chemo) induced neutropenia (CIN) prevention: Rationale for the combination.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12030-e12030.	1.6	0
42	Real-world efficacy of bone modifying agents (BMAs) in patients with breast cancer (BC) treated in an academic health system: Use of the "green button".. <i>Journal of Clinical Oncology</i> , 2019, 37, e18054-e18054.	1.6	1
43	A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (plin) + Pegfilgrastim (peg) Versus (vs) Peg Alone for Tac (docetaxel, doxorubicin, cyclophosphamide) Induced Neutropenia (cin). <i>Blood</i> , 2019, 134, 3590-3590.	1.4	0
44	Clinical Evidence Against the Continuum of Low-Primed Uncommitted Hematopoietic and Progenitor Cells (CLOUD-HSPC) Concept for Hematopoiesis. <i>Blood</i> , 2019, 134, 4860-4860.	1.4	0
45	Impact of mortality reviews on supportive care utilization, end-of-life care, and inpatient mortality.. <i>Journal of Clinical Oncology</i> , 2019, 37, 45-45.	1.6	1
46	Oncologists' Views on Using Value to Guide Cancer Treatment Decisions. <i>Value in Health</i> , 2018, 21, 931-937.	0.3	4
47	Efficacy of Medicaid for Patients With Cancer in California. <i>JAMA Oncology</i> , 2018, 4, 323.	7.1	4
48	Critical Lessons From High-Value Oncology Practices. <i>JAMA Oncology</i> , 2018, 4, 164.	7.1	23
49	Better, Safer, Cheaper: Joseph V. Simone Award and Lecture. <i>Journal of Oncology Practice</i> , 2018, 14, 763-766.	2.5	1
50	Architecture and Implementation of a Clinical Research Data Warehouse for Prostate Cancer. <i>EGEMS (Washington, DC)</i> , 2018, 6, 13.	2.0	31
51	P1.01-06 Plinabulin, a Novel Immuno-Oncology Agent Mitigates Docetaxel Chemotherapy-Induced-Neutropenia and -Thrombocytopenia in NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, S461.	1.1	3
52	Plinabulin (Plin), a novel non-G-CSF molecule for the revention of chemotherapy-induced neutropenia (CIN), has the potential to positively impact tumor micro environment. <i>Annals of Oncology</i> , 2018, 29, viii604.	1.2	0
53	Computing the cost of care per day of breast cancer survivor care.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10-10.	1.6	1
54	Practice-based evidence for factors associated with urinary incontinence following prostate cancer care.. <i>Journal of Clinical Oncology</i> , 2018, 36, 106-106.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase (I†) 2 results from a head-to-head comparison with Pegfilgrastim (Peg).. Journal of Clinical Oncology, 2018, 36, 2528-2528.	1.6	0
56	Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN) Prevention, Mobilizes CD34+ Cells through a Mechanism of Action (MoA) Different from G-CSF and from CXCR4 Inhibition. Blood, 2018, 132, 2068-2068.	1.4	0
57	Disrupted brain network functional dynamics and hyperâ€correlation of structural and functional connectome topology in patients with breast cancer prior to treatment. Brain and Behavior, 2017, 7, e00643.	2.2	66
58	The Appropriate Provision of Primary versus Specialist Palliative Care to Cancer Patients: Oncologists' Perspectives. Journal of Palliative Medicine, 2017, 20, 395-403.	1.1	25
59	Therapeutic Ultrasound as a Novel, Non-hormonal Treatment of Vulvo-vaginal Atrophy: A Pilot Phase II Study. Gynecologic Oncology, 2017, 147, 235.	1.4	0
60	Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1520-1541.	4.9	104
61	Predicting Long-Term Cognitive Outcome Following Breast Cancer with Pre-Treatment Resting State fMRI and Random Forest Machine Learning. Frontiers in Human Neuroscience, 2017, 11, 555.	2.0	58
62	Choosing Wisely in Oncology: Are We Ready For Value-Based Care?. Journal of Oncology Practice, 2017, 13, e935-e943.	2.5	37
63	Implementing a Method for Evaluating Patient-Reported Outcomes Associated With Oral Oncolytic Therapy. Journal of Oncology Practice, 2017, 13, e395-e400.	2.5	16
64	Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center. Journal of Oncology Practice, 2017, 13, e673-e682.	2.5	3
65	Redesigning Cancer Care Delivery: Views From Patients and Caregivers. Journal of Oncology Practice, 2017, 13, e291-e302.	2.5	52
66	A natural language processing algorithm to measure quality prostate cancer care.. Journal of Clinical Oncology, 2017, 35, 232-232.	1.6	5
67	New Paradigms for Patient-Centered Outcomes Research in Electronic Medical Records: An example of detecting urinary incontinence following prostatectomy. EGEMS (Washington, DC), 2017, 4, 1.	2.0	23
68	Survivorship care plan: Use of the â€Oncology Historyâ€™™ (OncHx) feature of the Epic electronic health record (EHR).. Journal of Clinical Oncology, 2017, 35, 51-51.	1.6	0
69	Patient reported symptom severity in cancer survivors.. Journal of Clinical Oncology, 2017, 35, 143-143.	1.6	0
70	Improving care with portfolio of physician-led cancer quality measures at an academic center.. Journal of Clinical Oncology, 2017, 35, 49-49.	1.6	0
71	Increasing Epic staging module adherence in an academic cancer center.. Journal of Clinical Oncology, 2017, 35, 64-64.	1.6	1
72	Mining Electronic Health Records to Extract Patient-Centered Outcomes Following Prostate Cancer Treatment. AMIA ... Annual Symposium proceedings, 2017, 2017, 876-882.	0.2	10

#	ARTICLE	IF	CITATIONS
73	Where Does Dynamic Value Assessment Fit Into Our Role as Agents Advising Our Patients With Cancer?. <i>Journal of Oncology Practice</i> , 2016, 12, 1211-1213.	2.5	2
74	Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. <i>Journal of Clinical Oncology</i> , 2016, 34, 3308-3314.	1.6	297
75	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. <i>Journal of Clinical Oncology</i> , 2016, 34, 2925-2934.	1.6	538
76	Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors. <i>JAMA Oncology</i> , 2016, 2, 185.	7.1	118
77	Plinabulin, a Novel Small Molecule That Ameliorates Chemotherapy-Induced Neutropenia, Is Administered on the Same Day of Chemotherapy and Has Anticancer Efficacy. <i>Blood</i> , 2016, 128, 2508-2508.	1.4	7
78	Using technology to improve quality metric adherence.. <i>Journal of Clinical Oncology</i> , 2016, 34, 257-257.	1.6	1
79	Choosing Wisely in oncology: Are we ready for value-based care?. <i>Journal of Clinical Oncology</i> , 2016, 34, 275-275.	1.6	0
80	Achieving the triple aim in cancer care through a tri-part research collaboration.. <i>Journal of Clinical Oncology</i> , 2016, 34, 52-52.	1.6	0
81	Using technology to improve patient-provider communication and delivery of quality care.. <i>Journal of Clinical Oncology</i> , 2016, 34, 76-76.	1.6	0
82	Using a web analytic tool to evaluate Pathways program engagement in 36 Michigan oncology practices.. <i>Journal of Clinical Oncology</i> , 2016, 34, 198-198.	1.6	0
83	The ideal interface between oncology and palliative care: Views from the field.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10034-10034.	1.6	0
84	What role should value play in cancer care?. <i>Journal of Clinical Oncology</i> , 2016, 34, 6629-6629.	1.6	0
85	Do Wise Choices Translate Into Cost Savings and Improved Outcomes?. <i>Journal of Oncology Practice</i> , 2015, 11, 344-345.	2.5	0
86	Are Patients With Thoracic Malignancies at Risk for Uncontrolled Symptoms?. <i>Journal of Oncology Practice</i> , 2015, 11, e98-e102.	2.5	8
87	Detecting Unplanned Care From Clinician Notes in Electronic Health Records. <i>Journal of Oncology Practice</i> , 2015, 11, e313-e319.	2.5	26
88	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015, 33, 2563-2577.	1.6	783
89	Administration of Oral Chemotherapy: Results From Three Rounds of the Quality Oncology Practice Initiative. <i>Journal of Oncology Practice</i> , 2015, 11, e255-e262.	2.5	18
90	Leveraging State Cancer Registries to Measure and Improve the Quality of Cancer Care: A Potential Strategy for California and Beyond. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv047-djv047.	6.3	27

#	ARTICLE	IF	CITATIONS
91	Transforming Data From Information to Quality Improvement: A Panel Discussion With Electronic Health Record Vendors. <i>Journal of Oncology Practice</i> , 2015, 11, 174-175.	2.5	2
92	Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. <i>Journal of Clinical Oncology</i> , 2015, 33, 2254-2261.	1.6	232
93	Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer. <i>Neurobiology of Aging</i> , 2015, 36, 2429-2442.	3.1	76
94	Choosing wisely: Treatment recommendations from 36 Michigan Oncology Clinical Treatment Pathways practices.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6584-6584.	1.6	0
95	Is screening enough? Implications of a pilot utilizing standard screening criteria for early palliative referral.. <i>Journal of Clinical Oncology</i> , 2015, 33, 119-119.	1.6	0
96	From PRO screening to improved wellness: A nurse-led intervention.. <i>Journal of Clinical Oncology</i> , 2015, 33, 72-72.	1.6	0
97	Development and Future of the American Society of Clinical Oncology's Quality Oncology Practice Initiative. <i>Journal of Clinical Oncology</i> , 2014, 32, 3907-3913.	1.6	24
98	Breast cancer treatment across health care systems: Linking electronic medical records and state registry data to enable outcomes research. <i>Cancer</i> , 2014, 120, 103-111.	4.1	48
99	Transforming Cancer Care: Are Transdisciplinary Approaches Using Design-Thinking, Engineering, and Business Methodologies Needed to Improve Value in Cancer Care Delivery?. <i>Journal of Oncology Practice</i> , 2014, 10, e51-e54.	2.5	15
100	Reply to L.K. Griffeth et al and J.E. Battley et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 2812-2813.	1.6	0
101	Patients with systemic lupus erythematosus and haematological malignancy at a tertiary care centre: timing, histopathology and therapy. <i>Lupus Science and Medicine</i> , 2014, 1, e000051.	2.7	14
102	Mobile cognitive assessment battery (MCAB) for assessment of cancer-related cognitive changes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9571-9571.	1.6	3
103	Measurement of urinary incontinence after prostate surgery from data-mining electronic health records (EHR).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6612-6612.	1.6	0
104	Survivorship care plan: Use of the "Oncology History" (OncHx) feature of the Epic electronic health record (EHR).. <i>Journal of Clinical Oncology</i> , 2014, 32, e20609-e20609.	1.6	0
105	Improved access to tobacco cessation services for cancer patients using a statewide collaborative approach.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6613-6613.	1.6	0
106	Oral chemotherapy performance indicators: Early results from three rounds of Quality Oncology Practice Initiative (QOPI) data.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6532-6532.	1.6	0
107	Abstract 5042: Using a statewide collaborative approach to improve tobacco cessation referral rates for cancer patients. , 2014, , .		0
108	Assessing the true nature of unplanned cancer care.. <i>Journal of Clinical Oncology</i> , 2014, 32, 183-183.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Building a patient-centered model: Palliative medicine and cancer care.. Journal of Clinical Oncology, 2014, 32, 75-75.	1.6	0
110	Models That Work: Incorporating Quality Principles in Different Clinical Settings. Journal of Oncology Practice, 2013, 9, 135-137.	2.5	6
111	Measuring and Improving Quality of Care in an Academic Medical Center. Journal of Oncology Practice, 2013, 9, 138-141.	2.5	6
112	American Society of Clinical Oncology 2013 Top Five List in Oncology. Journal of Clinical Oncology, 2013, 31, 4362-4370.	1.6	126
113	Computerized Prescriber Order Entry Implementation in a Physician Assistantâ€“Managed Hematology and Oncology Inpatient Service: Effects on Workflow and Task Switching. Journal of Oncology Practice, 2013, 9, e103-e114.	2.5	14
114	Introduction to the ASCO Quality Care Symposium. Journal of Oncology Practice, 2013, 9, 113-113.	2.5	0
115	Measuring the Improving Quality of Outpatient Care in Medical Oncology Practices in the United States. Journal of Clinical Oncology, 2013, 31, 1471-1477.	1.6	65
116	Tumor Boards (Team Huddles) Arenâ€™t Enough to Reach the Goal. Journal of the National Cancer Institute, 2013, 105, 82-84.	6.3	27
117	Myeloid Growth Factors. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1266-1290.	4.9	53
118	Real-time extraction of breast cancer treatment process and outcome measures from an EPIC electronic health record (EHR).. Journal of Clinical Oncology, 2013, 31, 1-1.	1.6	2
119	Using a statewide collaborative approach to improve tobacco cessation referral rates for cancer patients.. Journal of Clinical Oncology, 2013, 31, 74-74.	1.6	0
120	Using a statewide collaborative approach to improve primary palliative care performance.. Journal of Clinical Oncology, 2013, 31, 53-53.	1.6	0
121	Are patients' needs being met after hours? An evaluation of phone calls made after hours for patients with thoracic malignancies.. Journal of Clinical Oncology, 2013, 31, 46-46.	1.6	0
122	The Effect of Age on Delay in Diagnosis and Stage of Breast Cancer. Oncologist, 2012, 17, 775-782.	3.7	97
123	American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology. Journal of Clinical Oncology, 2012, 30, 1715-1724.	1.6	538
124	Michigan Oncology Practices Showed Varying Adherence Rates To Practice Guidelines, But Quality Interventions Improved Care. Health Affairs, 2012, 31, 718-728.	5.2	29
125	Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood, 2012, 119, 2093-2099.	1.4	88
126	Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Research and Treatment, 2012, 136, 813-821.	2.5	60

#	ARTICLE	IF	CITATIONS
127	The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy. <i>Quality of Life Research</i> , 2012, 21, 1255-1266.	3.1	13
128	Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2218-2226.	1.6	114
129	Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. <i>Cancer</i> , 2012, 118, 5463-5472.	4.1	469
130	Effect of intervention on quality measures of symptom management in the Michigan Oncology Quality Consortium (MOQC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 70-70.	1.6	2
131	Measuring the improving quality of outpatient care in medical oncology practices in the United States.. <i>Journal of Clinical Oncology</i> , 2012, 30, 66-66.	1.6	1
132	The use of a palliative care tool in a community private practice.. <i>Journal of Clinical Oncology</i> , 2012, 30, 95-95.	1.6	0
133	Institutional Variation in the Surgical Treatment of Breast Cancer. <i>Annals of Surgery</i> , 2011, 254, 339-345.	4.2	83
134	Myeloid Growth Factors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 914-932.	4.9	25
135	The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 897-904.	2.5	14
136	Commentary: Six Years of Trends in Oncology Practice Data. <i>Journal of Oncology Practice</i> , 2011, 7, 291-293.	2.5	2
137	Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence?. <i>Oncologist</i> , 2011, 16, 559-565.	3.7	8
138	P1-08-05: Age and Survival in Women with Early Stage Breast Cancer: An Analysis Controlling for Tumor Subtype.. , 2011, , .		0
139	Enhancing Quality Through Innovation: American Society of Clinical Oncology Presidential Address 2010. <i>Journal of Clinical Oncology</i> , 2010, 28, 4283-4288.	1.6	9
140	Challenges to National Cancer Institute-supported Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites. <i>Journal of Oncology Practice</i> , 2010, 6, 114-117.	2.5	19
141	Expansion of cancer care and control in countries of low and middle income: a call to action. <i>Lancet</i> , 2010, 376, 1186-1193.	13.7	615
142	Gene expression profile testing for breast cancer: Patterns and predictors of use and impact on chemotherapy.. <i>Journal of Clinical Oncology</i> , 2010, 28, 566-566.	1.6	3
143	Use of a 21-gene reverse transcriptase-polymerase chain reaction (RT-PCR) assay to guide therapy in 14 Michigan Breast Oncology Quality Initiative (MiBOQI) sites.. <i>Journal of Clinical Oncology</i> , 2010, 28, 6039-6039.	1.6	1
144	The effect of age on delay in diagnosis and stage of breast cancer.. <i>Journal of Clinical Oncology</i> , 2010, 28, 1580-1580.	1.6	0

#	ARTICLE	IF	CITATIONS
145	Impact of CPOE on workflow and direct patient care time in an inpatient hematology/oncology service.. Journal of Clinical Oncology, 2010, 28, 6142-6142.	1.6	0
146	Lymphoma After Solid Organ Transplantation: Risk, Response to Therapy, and Survival at a Transplantation Center. Journal of Clinical Oncology, 2009, 27, 3354-3362.	1.6	178
147	Partnering With Payers for Success: Quality Oncology Practice Initiative, Blue Cross Blue Shield of Michigan, and the Michigan Oncology Quality Consortium. Journal of Oncology Practice, 2009, 5, 281-284.	2.5	12
148	Implementation of the Quality Oncology Practice Initiative at a University Comprehensive Cancer Center. Journal of Clinical Oncology, 2009, 27, 3802-3807.	1.6	80
149	Myeloid Growth Factors. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 64-83.	4.9	96
150	See You in Chicago. Journal of Oncology Practice, 2008, 4, 107-107.	2.5	0
151	Hypoxia-Inducible Factor-1 Target Genes as Indicators of Tumor Vessel Response to Vascular Endothelial Growth Factor Inhibition. Cancer Research, 2008, 68, 1872-1880.	0.9	69
152	Diagnostic Images and Clinical Laboratory Results. Journal of Oncology Practice, 2008, 4, 1-1.	2.5	2
153	Strengths, Weaknesses, Opportunities, and Threats. Journal of Oncology Practice, 2008, 4, 53-53.	2.5	4
154	Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer. Journal of Clinical Oncology, 2008, 26, 5553-5560.	1.6	32
155	Development of the Anemia Impact Measure (AIM): A Disease-Specific Patient Reported Outcome (PRO) Instrument to Measure Anemia Symptoms and Their Impact on Functioning in Cancer Patients Receiving Chemotherapy. Blood, 2008, 112, 668-668.	1.4	1
156	Continued use of trastuzumab (TRZ) beyond disease progression in the National Comprehensive Cancer Network (NCCN). Journal of Clinical Oncology, 2008, 26, 6522-6522.	1.6	2
157	Implementation of Computerized Provider Order Entry (CPOE) Does Not Impact Provider Work Time in An Inpatient Malignant Hematology Service. Blood, 2008, 112, 4704-4704.	1.4	0
158	Challenges and Solutions. Journal of Oncology Practice, 2007, 3, 289-289.	2.5	0
159	From Bench to Benchmarking. Journal of Oncology Practice, 2007, 3, 1-1.	2.5	0
160	Pricing, Reimbursement, and Health Care Trends to Watch. Journal of Oncology Practice, 2007, 3, 181-181.	2.5	0
161	Translating Research Into Practice, Clinical Trials, and Process. Journal of Oncology Practice, 2007, 3, 111-111.	2.5	1
162	Who Will Do the Work? What Work Will They Do?. Journal of Oncology Practice, 2007, 3, 53-53.	2.5	0

#	ARTICLE	IF	CITATIONS
163	The Registry Case Finding Engine: An Automated Tool to Identify Cancer Cases from Unstructured, Free-Text Pathology Reports and Clinical Notes. <i>Journal of the American College of Surgeons</i> , 2007, 205, 690-697.	0.5	26
164	Eighty-Five Cases of Lymphoma in a Solid Organ Transplant (SOT) Population: Risk, Treatment, and Histologic Subtype.. <i>Blood</i> , 2007, 110, 1367-1367.	1.4	0
165	Making the Choice Between Academic Oncology and Community Practice: The Big Picture and Details About Each Career. <i>Journal of Oncology Practice</i> , 2006, 2, 132-136.	2.5	2
166	Increasing Chemotherapy Dose Density and Intensity: Phase I Trials in Nonâ€Small Cell Lung Cancer and Nonâ€Hodgkin's Lymphoma. <i>Oncologist</i> , 2005, 10, 138-149.	3.7	21
167	Myeloid Growth Factors Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005, 3, 540.	4.9	29
168	Efficacy of Darbepoetin Alfa in the Treatment of Chemotherapy-Induced Anemia in Non-Hodgkinâ€™s Lymphoma.. <i>Blood</i> , 2004, 104, 3296-3296.	1.4	0
169	Dose-Intense Chemotherapy Every 2 Weeks With Dose-Intense Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone May Improve Survival in Intermediate- and High-Grade Lymphoma: A Phase II Study of the Southwest Oncology Group (SWOG 9349). <i>Journal of Clinical Oncology</i> , 2003, 21, 2466-2473.	1.6	71
170	Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.. <i>Journal of Clinical Oncology</i> , 1998, 16, 2038-2044.	1.6	608
171	Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases. <i>New England Journal of Medicine</i> , 1996, 335, 1785-1792.	27.0	995
172	Association of intratumoral pharmacokinetics of fluorouracil with clinical response. <i>Lancet, The</i> , 1994, 343, 1184-1187.	13.7	173
173	High-risk germ cell tumors in men high response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide. <i>Cancer</i> , 1993, 71, 2351-2357.	4.1	9
174	Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. <i>Lancet, The</i> , 1993, 341, 1242-1243.	13.7	107
175	Phase II study of 4 ? -deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach. <i>Investigational New Drugs</i> , 1991, 9, 83-5.	2.6	0
176	Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 492-496.	7.1	105
177	Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.. <i>Journal of Clinical Oncology</i> , 1990, 8, 491-501.	1.6	221
178	Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics.. <i>Journal of Clinical Oncology</i> , 1990, 8, 1868-1873.	1.6	80
179	Proposed Criteria for Serial Evaluation of Quality of Life in Cancer Patients. <i>Journal of the National Cancer Institute</i> , 1990, 82, 322-323.	6.3	9
180	Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes. <i>Lancet, The</i> , 1990, 335, 1307-1309.	13.7	78

#	ARTICLE	IF	CITATIONS
181	A clinicopathologic study of malignant lymphomas of the nose, paranasal sinuses, and hard palate, including cases of lethal midline granuloma. <i>Cancer</i> , 1989, 64, 2525-2531.	4.1	91
182	Decreasing Risk of Leukemia with Prolonged Follow-up after Chemotherapy and Radiotherapy for Hodgkin's Disease. <i>New England Journal of Medicine</i> , 1987, 316, 710-714.	27.0	211
183	Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man. <i>American Journal of Medicine</i> , 1987, 83, 1055-1061.	1.5	60
184	Antigenically defined subgroups of lymphoblastic lymphoma. Relationship to clinical presentation and biologic behavior. <i>Cancer</i> , 1987, 60, 183-190.	4.1	90
185	Human immunodeficiency virus-associated T-cell lymphoblastic lymphoma in AIDS. <i>Cancer</i> , 1987, 60, 1459-1461.	4.1	46
186	High doses of prochlorperazine for cisplatin-induced emesis: A prospective, random, dose-response study. <i>Cancer</i> , 1987, 60, 2165-2169.	4.1	24
187	Lymphoblastic lymphoma expressing natural killer cell-associated antigens: A clinicopathologic study of six cases. <i>Leukemia Research</i> , 1987, 11, 371-377.	0.8	64
188	High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study.. <i>Journal of Clinical Oncology</i> , 1986, 4, 1058-1061.	1.6	40
189	Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. <i>Cancer</i> , 1986, 57, 492-498.	4.1	180
190	Spontaneous remission of Kaposi's sarcoma in an HTLV-III-negative homosexual man. <i>Cancer</i> , 1986, 58, 1583-1584.	4.1	10
191	Sclerosing Cholangitis after Continuous Hepatic Artery Infusiori of FUDR. <i>Annals of Surgery</i> , 1985, 202, 176-181.	4.2	147
192	Precautions in Care of Patients with the Acquired Immunodeficiency Syndrome. <i>Annals of Internal Medicine</i> , 1984, 101, 275.	3.9	0
193	Screening for Human T-Cell Leukemia-Lymphoma Virus-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1984, 251, 1555.	7.4	0
194	The pathologic spectrum of adult T-cell leukemia/lymphoma in the United States. <i>American Journal of Surgical Pathology</i> , 1984, 8, 263-276.	3.7	204
195	Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative SA©zary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor.. <i>Journal of Clinical Investigation</i> , 1984, 73, 1711-1718.	8.2	217
196	Epidemiology of Human T-Cell Leukemia/Lymphoma Virus. <i>Journal of Infectious Diseases</i> , 1983, 147, 406-416.	4.0	186
197	Clinical Course of Retrovirus-Associated Adult T-Cell Lymphoma in the United States. <i>New England Journal of Medicine</i> , 1983, 309, 257-264.	27.0	437
198	Proviral DNA of a retrovirus, human T-cell leukemia virus, in two patients with AIDS. <i>Science</i> , 1983, 220, 862-865.	12.6	264

#	ARTICLE	IF	CITATIONS
199	Evidence for human T cell lymphoma-leukemia virus infection of family members of human T cell lymphoma-leukemia virus positive T cell leukemia-lymphoma patients.. Journal of Experimental Medicine, 1983, 157, 248-258.	8.5	115
200	Isolation Procedures for Patients with Leukemia or Lymphoma Associated with Human T-Cell Leukemia Virus. New England Journal of Medicine, 1983, 308, 844-844.	27.0	6
201	The Human T-cell Leukemia/Lymphoma Virus, Lymphoma, Lytic Bone Lesions, and Hypercalcemia. Annals of Internal Medicine, 1983, 98, 144.	3.9	125
202	Retroviruses in human leukemia. Hematological Oncology, 1983, 1, 193-204.	1.7	8
203	Sarcoidosis and the Human T-cell Leukemia-Lymphoma Virus. Annals of Internal Medicine, 1983, 99, 409.	3.9	13
204	A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science, 1982, 218, 571-573.	12.6	1,147
205	Post-Splenectomy Demonstration of Splenic Tissue by Computed Tomography with Liposoluble Contrast Material. Journal of Computer Assisted Tomography, 1981, 5, 106-108.	0.9	1